DrugPipeline.net has announced the addition of Global Immunology Drugs Market to 2022 - Increasing Prevalence, Repositioning Opportunities and Strong Uptake of Interleukin Receptor Inhibitors to Drive Growth research report to their website http://www.DrugPipeline.net

This press release was orginally distributed by SBWire

Bangalore, India -- (SBWIRE) -- 08/07/2017 -- Global Immunology Drugs Market to 2022 - Increasing Prevalence, Repositioning Opportunities and Strong Uptake of Interleukin Receptor Inhibitors to Drive Growth

Summary

Immunology is a therapy area characterized by disorders of the immune system, specifically an aberrant autoimmune response against healthy tissues in the body, leading to chronic or acute inflammation. Depending on the specific site affected, this can lead to various types of chronic pain and mobility loss, and have a negative impact on quality of life.

A number of therapies have been approved for immunological disorders, including the largely genericized disease-modifying anti-rheumatic drug (DMARD) class of small molecule drugs. However, as these therapies often fail to elicit an adequate long-term response, a large second-line therapy segment has emerged in these markets, beginning with the approval of Remicade (infliximab) and Enbrel (etanercept) in 1998. There is currently no cure for immunological disorders due to the highly complex nature of the immune system and the fact that many components of the pathophysiological states of these diseases have roles in the healthy immune system.

Autoimmune disorders are currently incurable, and treatment is aimed at managing the disease, in order to reduce the severity of its symptoms and lower the risk of associated co-morbidities. Cytokines and their receptors, such as Tumor Necrosis Factor-? and Interleukin-6 are the most effective and most common therapies used in immunology. This class of compounds has been the most commercially successful in the past decade, particularly in the RA market, with many clinical trials underway across various immunological indications. The market for immunological disorders is largely accounted for by premium products, with only a relatively small revenue share accounted for by generics and biosimilars.

Inflectra, a biosimilar of Remicade was recently approved by the FDA in 2016. However, the gradual uptake of biosimilars such as Inflectra is not expected to act as a strong growth driver for the biosimilar segment within the forecast period. This therefore means existing products such as Remicade are expected to maintain high revenues during the forecast period

Although there is a high degree of failure and uncertainty in R&D of immunological drugs, there are 2,054 drugs in active development in the immunology pipeline. In the long-term, this is expected to drive growth in this market in spite of the anticipated approval of biosimilars for key blockbuster drugs and resultant erosion of revenues. Cytokines and their receptors account for the largest single segment of each of the pipelines which make up the largest individual class.

The report focuses on four key indications within immunology: Rheumatoid arthritis, Systemic lupus erythematosus (SLE), Psoriasis and Inflammatory bowel disease (The two major types of Inflammatory bowel disease covered in this report are Ulcerative colitis and Crohn's disease). With no curative therapies available, symptomatic medications prescribed off-label are an important part of the treatment paradigm, especially in SLE, increasing the need for extensive R&D within this area.

Scope

- Global revenues for the immunology market are forecast to grow at a compound annual growth rate of 3.63%, from $57.7 billion in 2015 to $74.1 billion in 2022.

- Which drugs will achieve blockbuster status and how will the key player companies perform during the forecast period?

- The immunological disorders pipeline is large and diverse, and contains 2,054 products. How does the composition of the pipeline compare with that of the existing market?

- What molecular targets and molecule types are most commonly being trialed in pipeline products in the key indications?

- Which products will contribute to market growth most significantly, and which will achieve blockbuster status?

- Will the current market leaders retain their dominance over the forecast period, and how is their revenue share of the immunology market set to change?

Reasons to buy

- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis

- Visualize the composition of the immunology market across each indication, in terms of dominant molecule types and targets, highlighting the key commercial assets and players

- Analyze the immunological disorders pipeline and stratify by stage of development, molecule type and molecular target, with a granular breakdown across key indications

- Understand the growth in patient epidemiology and market revenues for the immunology market, globally and across the key players and product types

- Stratify the market in terms of the split between generic and premium products, and assess the role of these product types in the treatment of the various immunological disorders.

- Identify commercial opportunities in the immunology deals landscape by analyzing trends in licensing and co-development deals

Spanning over 140 pages "Global Immunology Drugs Market to 2022 - Increasing Prevalence, Repositioning Opportunities and Strong Uptake of Interleukin Receptor Inhibitors to Drive Growth" report covers Introduction, Key Marketed Products, Pipeline Landscape Assessment, Multi-scenario Market Forecast to 2022, Company Analysis and Positioning, Strategic Consolidations, Appendix.

For more information Visit at: http://www.drugpipeline.net/gbi-research/global-immunology-drugs-market-2022-increasing-prevalence-repositioning-opportunities

Find all Pharma and Healthcare Reports at - http://www.drugpipeline.net/catalog/pharma-healthcare

Related Reports;

Pain Drug Development Pipeline Review, 2017 - Visit at - http://www.drugpipeline.net/gbi-research/pain-drug-development-pipeline-review-2017

Skeletal Disease Drug Development Pipeline Review, 2017 - Visit at - http://www.drugpipeline.net/gbi-research/skeletal-disease-drug-development-pipeline-review-2017

About DrugPipeline.netDrugPipeline.net is a market research reports distribution platform which hosts research reports from all leading global market research firms related to pharma industry. It also assist decision makers locate the right market research solution from a single place.

For more information on this press release visit: http://www.sbwire.com/press-releases/global-immunology-drugs-market-to-2022-new-report-launched-843163.htm

See the article here:
Global Immunology Drugs Market to 2022; New Report Launched - Digital Journal

Boys Town National Research Hospital

Boys Town Allergy, Asthma Immunology & Pediatric Pulmonology Welcomes New Physician

Brian T. Kelly, M.D., M.A. joined Boys Town Allergy, Asthma & Immunology on August 1, 2017 from St. Paul Allergy and Asthma in Minnesota. He received his medical degree from the University of Missouri-Kansas City School of Medicine and completed his pediatric residency at Children's Hospital of Wisconsin. In addition, Dr. Kelly completed a fellowship in allergy/clinical immunology at the Medical College of Wisconsin. He is board certified in pediatrics and allergy/immunology. He is accepting new patients at Boys Town Pediatrics Lakeside Clinic located at 16929 Frances Street, Suite 101.

Read the original:
Boys Town Allergy, Asthma Immunology & Pediatric Pulmonology - Omaha World-Herald

A nationwide manhunt is underway for a Northwestern University professor and an Oxford University employee who are wanted as suspects after a man was found fatally stabbed inside a luxury Chicago apartment, police said.

On Monday, first-degree murder warrants without bail were issued for Wyndham Lathem, 42, and Andrew Warren, 56, for their alleged involvement in the death of Trenton H. James Cornell-Duranleau, Cook County court records show.

The documents say Cornell-Duranleau, 26, died after being stabbed multiple times. A community alert released by the Chicago Police Department says the body was discovered on July 27.

via Facebook

Officers received a call and arrived at the Grand Plaza Apartments and found the victim with several lacerations on his body. Cornell-Duranleau was pronounced dead on the scene and detectives are investigating the stabbing as a homicide while police actively search for the two suspects, officials said.

Lathem has been an associate professor of microbiology and immunology at Northwestern University since 2007. Alan K. Cubbage, the vice president for university relations, said in an emailed statement that Lathem is now on administrative leave and has been banned from entering Northwestern University campuses.

Wyndham Lathem is an associate professor of microbiology and immunology at Northwestern University. Chicago Police via AP

This is now a criminal matter under investigation by the appropriate authorities, and Northwestern University is cooperating in that investigation, Cubbage said.

Warren is a senior treasury assistant at Oxford University. A spokesperson for the university and Somerville College said in an emailed statement that, We have been in contact with the police in the UK and are ready to help the US investigating authorities in any way they need. The statement added that Warrens colleagues were shocked and want him to turn himself in.

Oxford University employee Andrew Warren Chicago Police via EPA

Chief Communications Officer of the Chicago Police Department Anthony Guglielmi said he strongly encourages the suspects to surrender to authorities. Police have an idea of their whereabouts but our efforts to locate that are intensifying, Guglielmi said.

Guglielmi said local, regional and national authorities are helping find the suspects. Guglielmi said police received a call from the Grand Plaza building manager who had just received a cryptic tip that said something had occurred in apartment 1008. Police described the scene as very gruesome. Guglielmi said it is unclear if the incident also occurred on July 27. Lathem and Warren were confirmed to be at the building by security cameras, he said.

Police said Lathem lived at the apartment that has since been identified as the crime scene.

We believe Professor Latham and the victim had a relationship, Guglielmi said. He added that both suspects' passports and Warren's travel visa have been flagged. Police also confirmed that the two suspects donated $1,000 to a Wisconsin library in the victim's name.

The management team at Grand Plaza said in a statement to residents: Police are currently working on the timeline and background of the victim and are exploring a variety of motives, including a possible domestic incident.

Continued here:
Northwestern Professor and Oxford University Employee Wanted for Homicide - NBCNews.com

A Northwestern University associate professor and a University of Oxford employee are wanted in connection with the stabbing death of a man in a Near North Side apartment, according to public records. A Cook County judge issued arrest warrants Monday charging Wyndham Lathem, 42, and Andrew Warren, 56, with first-degree murder in the death of 26-year-old Trenton Cornell-Duranleau last week, records show.

An alert broadcast over police radio says the two should be considered armed and dangerous. Late Wednesday afternoon, Chicago police spokesman Anthony Guglielmi reported no arrests.

"Our search will only intensify,'' tweeted Guglielmi. "Prof Latham (Lathem) & Mr Warren, do the right thing & turn yourself in to any police dept.''

Lathem is an associate professor at Northwestern's Department of Microbiology-Immunology at the Feinberg School of Medicine. In his LinkedIn profile, Lathem said his research is focused on pathogens and the diseases they cause.

Lathem has been placed on administrative leave and is banned from all Northwestern campuses, according to school spokesman Alan K. Cubbage. He was a faculty researcher at the school's Chicago campus.

The university is cooperating with the police investigation, Cubbage said.

Warren is a senior treasury assistant at Somerville College, part of the Oxford University network, according to a university web page. Chicago police officers responded to a 10th-floor apartment in the 500 block of North State Street about 8:30 p.m. Thursday after a maintenance worker reported getting an anonymous call that a crime was committed there. Officers found Cornell-Duranleau dead on the scene. Lathem lists his home at the same address on State Street, public records show. The building is on the same block as the Grand Avenue Red Line station.Cornell-Duranleau died of multiple sharp force injuries, according to the Cook County medical examiners office. He had lived in the 2200 block of South Wood Street in the Heart of Chicago neighborhood on the Near Southwest Side, the office said.

He grew up in Michigan, according to public records. Cornell-Duranleau earned a state license as a cosmetologist in 2011, according to the Michigan Department of Licensing and Regulatory Affairs.

Chicago Police Department

His mother, Mischelle Duranleau, posted a message on Facebook over the weekend asking for prayers "as we navigate this very dark part of our Journey."

According to an obituary posted by the mother, Cornell-Duranleau was born in Lennon, Mich., a small town about 50 miles northeast of Lansing.

"Throughout his life he loved music and animals," the obituary said. "His enthusiasm for life was infectious. Trenton was a caregiver and loved to help others. His youthful free-spirit fueled his love of cars, video games and cartoons."

Northwestern was made aware of the investigation into Cornell-Duranleau's death on Monday afternoon, Cubbage said.

Lathem has been with Northwestern since 2007, according to Cubbage, who said he worked primarily in a research lab. "At some point in the past few years he taught medical students or graduate students, never undergrad, Cubbage said.

Lathem was not currently teaching and was not scheduled to be in a classroom in the fall, Cubbage said.

Oxford University, where the other suspect worked, released a statement Tuesday saying it was "not aware of this case, which is clearly extremely concerning. We will liaise with the relevant investigating authorities and provide any assistance that is required.

More:
Arrest warrant issued for Northwestern professor in Near North Side stabbing death - Chicago Tribune

Shire has kickstarted a strategic review of its ADHD drugs business which could see the FTSE 100 giant broken up into two stock exchange-listed parts, after posting consensus-beating half-year sales and profits growth.

Flemming rnskov, chief executive at Shire, said the groups US-focused neurosciences division set to make up around a fifth of its projected $14.3bn-$14.6bn (10.9bn-11.1bn) sales this year was an incredibly strong business that could stand alone.

The strategic review will complete this year, with the firm saying it could result in neurosciences getting an independent public listing. Mr rnskov declined to say whether London or New York was the more likely candidate.

Given the USs large appetite for ADHD drugs, New York could hold appeal.Julie Simmonds, analyst at Panmure, commented: Its something they could look at, it would make as much sense as it would here.

Any separation would allow Shire to focus on its rare diseases business, which accounts for the bulk of revenues and a wide gamut of treatments across immunology, haematology, internal medicine, eye ailments, oncology and anti-virals.

Read the original here:
Shire eyes spin-out of its ADHD drugs arm - Telegraph.co.uk

MONTREAL, July 31, 2017 /CNW Telbec/ - IRICoR (Institute for Research in Immunology and Cancer - Commercialization of Research) proudly announces the appointment of Dr. Martin Godbout, president of Hodran Consultants Inc., as the new Chairman of its Board of Directors and of Ms. Catherine Bouchard, Head of Research, Life Sciences at the Caisse de dpt et placement du Qubec, as a new Board member.

Dr. Godbout brings to IRICoR's Board a deep expertise in the health sciences sector. With his thorough knowledge of the field and his close to 30-year experience, he will greatly contribute to IRICoR's ongoing initiatives to attract and accelerate the development of promising innovative projects in oncology. Dr. Godbout started his professional career as President and CEO of Socit Innovatech Qubec, a technology-focused venture capital (VC) fund. He then served as Executive Vice-president of BioCapital, a biopharmaceutical VC firm, after which he founded Genome Canada, which he successfully led for more than 10 years as CEO. He was also a Board member of numerous biopharmaceutical companies, not-for-profit organizations involved in funding research and innovation and philanthropic organizations. He is currently Chair of the Board at Amorchem-I, BioContact, BioQubec and Genome Quebec, and a Board Member of various organizations, including the Fonds de recherche du Qubec Sant. Dr. Godbout holds a B.Sc. in Biochemistry and a Ph.D. in Physiology and Molecular Endocrinology from Universit Laval. He completed his post-doctoral training in Molecular Neurobiology at San Diego'sScripps Research Institute. Finally, Dr. Godbout is an Officer at the Order of Canada.

"We enthusiastically welcome Dr. Godbout to IRICoR's team. His diverse professional expertise both in the healthcare and business sectors, as well as his broad professional network will be critical to the success of IRICoR's ongoing strategic initiatives."Nadine Beauger, Chief Executive Officer - IRICoR

Dr. Godbout succeeds Johane Boucher-Champagne who was Chair of IRICoR's Board since 2011, after having been a member since 2009. IRICoR takes this opportunity to formally thank Mrs. Boucher-Champagne for having put her deep experience in the life science sector to the service of IRICoR. She has truly been a key resource for the organization through all those years.

"Through her deep knowledge of the pharmaceutical sector and her keen governance skills, Mrs. Boucher-Champagne skillfully managed to further IRICoR's initiatives, leading the organization to become a leader in commercialization of research. We are very grateful for Mrs. Boucher-Champagne's 8 years of continuous commitment."Michel Bouvier, Chief Executive Officer and Principal Investigator, IRIC (Institute for Research in Immunology and Cancer)

Catherine Bouchard has more than 10 years of experience in healthcare equity research. She is currently Head of Research, Life Sciences at the Caisse de dpt et placement du Qubec, where she has served as Senior Healthcare Analyst since 2012. Prior to joining CDPQ, Ms. Bouchard spent 5 years at Valeurs Mobilires Banque Laurentienne, where she was the Lead Analyst covering healthcare stocks. Her expertise in industry analysis and her deep knowledge of the healthcare sector will be key additions for IRICoR. She holds a B.Sc. in Microbiology and Immunology and an M.Sc. in Biomedical Sciences from Universit de Montral, as well as an MBA from HEC Montreal.

Dr. Godbout and Ms. Bouchard are joining a Board that stands out for its Members' deep commitment, diverse expertise in both health sciences and business matters, as well as its extended network.

About the Institute for Research in Immunology and Cancer Commercialization of Research (IRICoR)

As Universit de Montral's drug discovery and project maturation cluster, IRICoR is a not-for-profit organization based at the Institute for Research in Immunology and Cancer (IRIC), with the mandate to accelerate the discovery, development and commercialization of novel therapies in cancer, immunotherapy and related fields. Since its creation in 2008, IRICoR successfully invests in and supports cutting-edge projects with disruptive potential to rapidly translate innovation into patient-accessible therapies, through either co-development partnerships with industry or company creation. IRICoR seamlessly integrates business-related expertise with industry-level drug discovery in a world-renowned research institute, providing academics with access to a full drug discovery chain with one of the largest academia-based medicinal chemistry groups in Canada. For more information about IRICoR: http://www.iricor.ca

About the Institute for Research in Immunology and Cancer (IRIC)

An ultra-modern research hub and training centre located in the heart of the Universit de Montreal, the Institute for Research in Immunology and Cancer (IRIC) was created in 2003 to shed light on the mechanisms of cancer and discover new, more effective therapies to counter this disease. IRIC operates according to a model that is unique in Canada. Its innovative approach to research has already led to discoveries that will, over the coming years, have a significant impact on the fight against cancer. For further information visit http://www.iric.ca

About the University of Montreal

Deeply rooted in Montreal and dedicated to its international mission, the University of Montreal is one of the top 100 universities in the world. It was founded in 1878, and together with its two affiliated schools, HEC Montral and Polytechnique Montral, constitutes the largest centre of higher education and research in Quebec and one of the major centres in North America. The University of Montreal brings together more than 2,700 professors and researchers and welcomes more than 68,000 students. http://www.umontreal.ca

SOURCE Institut de recherche en immunologie et en cancrologie de l'Universit de Montral

Continue reading here:
IRICoR announces the appointment of Dr. Martin Godbout as Chairman of its Board of Directors and of Ms. Catherine ... - Markets Insider

Eli Lilly is bolstering its autoimmune offerings with a new co-development and commercialization agreement.

The deal will focus on a promising drug called NKTR-358, developed by Nektar Therapeutics. Its being designed to target the interleukin (IL-2) receptor complex in the body in an effort to stimulate the proliferation of regulatory T-cells. Activating these cells could bring the immune system back into balance.

As part of this agreement, Nektar will receive an initial payment of $150 million from Eli Lilly with the potential to receive an estimated $250 million if the drug achieves certain development and regulatory milestones, according to the announcement.

Investigators achieved the first human dose of NKTR-358 as part of a Phase I clinical trial in March 2017 with the goal of measuring observed changes and functional activity of regulatory T cells in approximately 50 healthy patients.

Both companies will co-develop NKTR-358 with Nektar being responsible for completing Phase 1 clinical development, but then the costs will shift for Phase 2 in which Lilly will handle 75 percent and Nektar the remaining 25 percent.

Furthermore, Nektar will be able to receive double-digit royalties that increase based on its Phase III investment and product sales with Lilly handling all costs of global commercialization.

"We are very pleased to enter into this collaboration with Lilly as they have strong expertise in immunology and a successful track record in bringing novel therapies to market," said Nektars President and CEO Howard W. Robin, in a statement. Importantly, this agreement enables the broad development of NKTR-358 in multiple autoimmune conditions in order to achieve its full potential as a first-in-class resolution therapeutic."

Proving this drugs mechanism of action is viable could ultimately yield a multi-purpose therapy that could work for autoimmune conditions like lupus and psoriasis.

Excerpt from:
Eli Lilly Signs Development Deal for Novel Immunology Drug - Drug Discovery & Development

It pains me to write this post, because Dak Prescott seems fairly unimpeachable character-wise. Especially after reading this Sports Illustrated interview, in which last years Rookie of the Year talks about his effort to raise $150,000 to bolster awareness to immunology research in the wake of his mothers death from cancer in 2013. He also dings Zeke for his ESPN the Magazine Body Issue cover, saying he should use his platform to do things like Im doing such asthis cancer campaign instead of doing his thing for the body issue and doing photo shoots.

Side-eye notwithstanding, look at that character!

I wish Id stopped reading there.SI just had to include this tidbit:

SI:Favorite song right now?

Prescott:My favorite song ever isDrops of Jupiterby Train. Its one of the songs I listen to before games. Its chill, but its also upbeat at the same time.

But, you know what, if that gets him going, Cowboys fans cant really complain too much. Maybe thats why he seems so calm in the pocket.Anyway, head here to learn more about the Ready. Raise. Rise. campaign that Prescotts aligning withtoraise money for immunology research; its a dual effort with Bristol-Myers Squibb.

Here is the original post:
Dak Prescott: Great Guy Who Gets Pumped to Bad Music - D Magazine

Not the sun, but a microscopic look at a specific gene in a specific cell that has led to a major advance in our understanding and treatment of auto-immune diseases. Photo Credit: Ciriaco Piccirillo, Research Institute of the McGill University Health Centre

It was one of those tragic cases in medicine.

A newly born child, just weeks old, had a severe auto-immune condition that could not be treated and which led irrevocably to his death.

With just a few drops of the childs blood, researchers led by a team in McGill University and the Research Institute-McGill University Health Centre (RI-MUHC) in Montreal, have painstakingly discovered the cause in a subset of so-called T-cells, and have created a solution that has major disease treatment implications.

Dr. Ciriaco Piccirillo led an international research team with input from the USA and Japan. He is an immunologist and senior scientist with the Infectious Diseases and Immunity in Global Health Programat the Research Institute-McGill University Health Centre (RI-MUHC), and a Professor of Immunology and Medicine at McGill University. He is also the Director of the newly created Centre of Excellence in Translational Immunology (CETI) at the RI-MUHC.

The baby boy died in 2009 of a rare and often fatal inherited genetic immune disorder called IPEX. The case involved the childs T-cells, and specifically the Treg cell, the immunosuppressive cells of the immune system.

These latter are a special kind of white blood cells or lymphocytes that regulate the bodies auto-immune response. They prevent other immune cells from attacking the bodys own tissues, as well as controlling immune responses against microbes and other non-pathogenic agents, such as pollen, dust or benign food groups. This is an important self-check built into the immune system to prevent excessive reaction.

When the immune response is not controlled it can cause damage to the body in diseases such as rheumatoid arthritis, Lupus, and Crohns disease as well as broader conditions such as asthma, allergies and cancer.

Through meticulous molecular research and availability of new highly sophisticated technology at the RI-MUHC, the team was able to determine a defect in a particular gene in the Treg cell which prevented it from properly acting in its regulatory role in dampening the immune system response.

Certain genes, but especially the FOXP3 gene are responsible for programming so-to-speak a T-cell to become a Treg cell.

What the team found from the babys blood was a rare mutation of the FOXP3 gene which negatively impacted its capacity to promote Treg cell development and function in humans.

After the intense research to detect the genetic defect in the specific FOXP3 gene, they developed a drug which appears able to correct the genetic defect resulting in an almost completely normally functioning Treg cell.

The teams research was published in the online journal Science-Immunology under the title Suppression by human FOXP3+ regulatory T cells requires FOXP3-TIP60 interactions (abstract HERE)

Further, while this should work in those rare patients with IPEX, professor Piccirillo says the team in now working on improving the drug to bolster its effects on the FOXP3 gene and developing Treg cells in other inflammatory and autoimmune diseases.

He says this likely will have far greater treatment possibilities in relation to a number of auto-immune diseases which are typically very difficult to treat.

The study was funded by the Canadian Institutes of Health Research, Canada Research Chair Program, National Institutes of Health and the Abramson Family Cancer Research Institute.

Go here to see the original:
A few drops of blood lead to a breakthrough in immunology - Radio Canada International

Research ArticleDENDRITIC CELLS

* These authors contributed equally to this work.

Present address: INSERM U955, IMRB Equipe-16, VRI, F-94010, Creteil, France.

Present address: Drukier Institute for Childrens Health, Weill Cornell Medical College, New York, NY 10021, USA.

+ See all authors and affiliations

Science Immunology 07 Jul 2017: Vol. 2, Issue 13, eaai8071 DOI: 10.1126/sciimmunol.aai8071

Aymeric Silvin

Immunity and Cancer Department, Institut Curie, PSL Research University, INSERM U932, 75005 Paris, France.

Chun I Yu

Baylor Institute for Immunology Research, Dallas, TX 75204, USA.The Jackson Laboratory for Genomic Medicine, Farmington, CT 06032, USA.The Jackson Laboratory, Bar Harbor, ME 04609, USA.

Xavier Lahaye

Immunity and Cancer Department, Institut Curie, PSL Research University, INSERM U932, 75005 Paris, France.

Francesco Imperatore

Centre dImmunologie de Marseille-Luminy, Aix Marseille University, UM2, INSERM U1104, CNRS UMR7280, France.

Jean-Baptiste Brault

Institut Curie, PSL Research University, CNRS, UMR144, Molecular Mechanisms of Intracellular Transport, 75005 Paris, France.

Sylvain Cardinaud

Centre dImmunologie et des Maladies Infectieuses-Paris, Pierre and Marie Curie University UMRS C7, INSERM U1135, CNRS ERL 8255, Paris, France.INSERM U955, IMRB Equipe-16, Vaccine Research Institute (VRI), F-94010, Creteil, France.

Christian Becker

Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine; and Immunology Institute, Mount Sinai School of Medicine, New York, NY 10029, USA.

Wing-Hong Kwan

Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

Ccile Conrad

Immunity and Cancer Department, Institut Curie, PSL Research University, INSERM U932, 75005 Paris, France.

Mathieu Maurin

Immunity and Cancer Department, Institut Curie, PSL Research University, INSERM U932, 75005 Paris, France.

Christel Goudot

Immunity and Cancer Department, Institut Curie, PSL Research University, INSERM U932, 75005 Paris, France.

Santy Marques-Ladeira

Immunity and Cancer Department, Institut Curie, PSL Research University, INSERM U932, 75005 Paris, France.

Yuanyuan Wang

Baylor Institute for Immunology Research, Dallas, TX 75204, USA.

Virginia Pascual

Baylor Institute for Immunology Research, Dallas, TX 75204, USA.

Esperanza Anguiano

Baylor Institute for Immunology Research, Dallas, TX 75204, USA.

Randy A. Albrecht

Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

Matteo Iannacone

Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.

Adolfo Garca-Sastre

Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

Bruno Goud

Institut Curie, PSL Research University, CNRS, UMR144, Molecular Mechanisms of Intracellular Transport, 75005 Paris, France.

Marc Dalod

Centre dImmunologie de Marseille-Luminy, Aix Marseille University, UM2, INSERM U1104, CNRS UMR7280, France.

Arnaud Moris

Centre dImmunologie et des Maladies Infectieuses-Paris, Pierre and Marie Curie University UMRS C7, INSERM U1135, CNRS ERL 8255, Paris, France.

Miriam Merad

Precision Immunology Institute, Human Immune Monitoring Center, Tisch Cancer institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

A. Karolina Palucka

Baylor Institute for Immunology Research, Dallas, TX 75204, USA.The Jackson Laboratory for Genomic Medicine, Farmington, CT 06032, USA.The Jackson Laboratory, Bar Harbor, ME 04609, USA.

Nicolas Manel

Immunity and Cancer Department, Institut Curie, PSL Research University, INSERM U932, 75005 Paris, France.

Read more from the original source:
Constitutive resistance to viral infection in human CD141 - Science (subscription)